Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients.

ABSTRACT:

Aim

To investigate the clinical utility of serum annexin A2 (ANXA2) as a diagnostic marker for early hepatocellular carcinoma (HCC).

Methods

This study was performed in HCC Clinic of Ain Shams University Hospitals, Cairo, Egypt and included: Group 1: Fifty patients with early stage HCC (Barcelona Clinic Liver Cancer stage A); Group 2: Twenty five patients with chronic liver disease; and Control Group: Fifteen healthy, age- and sex-matched subjects who were seronegative for viral hepatitis markers. The following laboratory investigations were done: Viral hepatitis markers [hepatitis B surface antigen and hepatitis C virus (HCV) antibodies], HCV RNA in HCV antibody-positive patients, serum alpha fetoprotein (AFP), and serum ANXA2 levels.

Results

In this study, 88% of HC

SUBMITTER: Shaker MK 

PROVIDER: S-EPMC5368624 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature